Home > Insider Trading > Filing (0000899243-20-009633)

Filing Details

Accession Number:: 0000899243-20-009633
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-30 11:34:19
Reporting Period:: 2020-03-26

Accepted Time:: 2020-03-30 11:34:19
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1679082	Myovant Sciences Ltd.	MYOV	()	M0

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1446601	Dainippon Sumitomo Pharma Co Ltd	6-8 Doshomachi 2-Chome Chuo-Ku, Osaka M0 541-0045	No	No	Yes	No
1798244	Ltd. Biopharma Sumitovant	11-12 St. James'S Square Suite 1 3Rd Floor London X0 SW1Y 4LB	No	No	Yes	No
1798550	Sumitomo Chemical Co., Ltd.	27-1, Shinkawa 2-Chome Chuo-Ku, Tokyo M0 104-8260	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-26	70,000	$7.94	46,578,604	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2020-03-27	70,000	$7.98	46,648,604	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan").
The price reported in column 4 is the average stock price.
Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 46,578,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan.
Sumitovant directly owns 46,648,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.